Biogen Inc. (NASDAQ:BIIB) Director Alexander J. Denner purchased 30,000 shares of Biogen stock in a transaction on Wednesday, November 29th. The shares were acquired at an average cost of $317.36 per share, with a total value of $9,520,800.00. Following the completion of the transaction, the director now directly owns 10,029 shares in the company, valued at approximately $3,182,803.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Biogen Inc. (NASDAQ:BIIB) traded down $2.82 during trading on Friday, reaching $319.35. 1,204,605 shares of the company were exchanged, compared to its average volume of 963,390. Biogen Inc. has a 1 year low of $244.28 and a 1 year high of $348.84. The firm has a market cap of $68,131.52, a PE ratio of 14.92, a P/E/G ratio of 2.01 and a beta of 0.73. The company has a quick ratio of 1.90, a current ratio of 2.19 and a debt-to-equity ratio of 0.46.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.70 by $0.61. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The firm had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter last year, the company earned $5.19 EPS. The firm’s revenue for the quarter was up 4.1% compared to the same quarter last year. sell-side analysts predict that Biogen Inc. will post 22.03 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in BIIB. Prentiss Smith & Co. Inc. grew its stake in Biogen by 14.9% in the 2nd quarter. Prentiss Smith & Co. Inc. now owns 385 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 50 shares during the period. Atlantic Trust LLC acquired a new stake in Biogen in the 2nd quarter valued at $114,000. Independent Portfolio Consultants Inc. grew its stake in Biogen by 93.2% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 454 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 219 shares during the period. Horan Capital Advisors LLC. acquired a new stake in Biogen in the 3rd quarter valued at $128,000. Finally, Massey Quick Simon & CO. LLC grew its stake in Biogen by 84.8% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 425 shares of the biotechnology company’s stock valued at $133,000 after acquiring an additional 195 shares during the period. 87.76% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have issued reports on the stock. Mizuho set a $400.00 price target on shares of Biogen and gave the stock a “buy” rating in a research report on Monday, November 13th. Goldman Sachs Group raised shares of Biogen from a “buy” rating to a “conviction-buy” rating and set a $338.00 price target for the company in a research report on Wednesday, August 16th. Vetr lowered shares of Biogen from a “buy” rating to a “hold” rating and set a $316.82 price target for the company. in a research report on Monday, September 4th. Morgan Stanley raised shares of Biogen from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $311.00 to $375.00 in a research report on Thursday, October 5th. Finally, ValuEngine lowered shares of Biogen from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Twelve equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $344.32.

COPYRIGHT VIOLATION WARNING: This story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.watchlistnews.com/alexander-j-denner-buys-30000-shares-of-biogen-inc-biib-stock/1739452.html.

About Biogen

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Insider Buying and Selling by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.